Alaunos Therapeutics
TCRT
145 hedge funds and large institutions have $242M invested in Alaunos Therapeutics in 2020 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 52 increasing their positions, 33 reducing their positions, and 23 closing their positions.
231% more capital inflows, than outflows
Capital inflows: $51.3M | Capital outflows: $15.5M
58% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 33
29% more call options, than puts
Call options by funds: $4.41M | Put options by funds: $3.42M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 23
1.01% less ownership
Funds ownership: 47.36% → 46.36% (-1%)
2% less funds holding
Funds holding: 148 → 145 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Discovery Capital Management
South Norwalk,
Connecticut
|
+$16.7M |
| 2 |
EcoR1 Capital
San Francisco,
California
|
+$12.9M |
| 3 |
BlackRock
New York
|
+$5.01M |
| 4 |
Renaissance Technologies
New York
|
+$2.29M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.74M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.87M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$901K |
| 4 |
D.E. Shaw & Co
New York
|
-$639K |
| 5 |
Squarepoint
New York
|
-$626K |
TCRT Hedge Fund Activity: Q1 2020 in Review
145 of the 4,552 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2020, worth a combined $242M — down 40% from $404M a quarter earlier.
Fund positioning in TCRT was balanced in Q1 2020: 23 funds opened new positions, 23 closed out, 52 added to existing stakes and 33 trimmed.
The largest buyer was Discovery Capital Management, adding an estimated $16.7M. The largest seller was Millennium Management, cutting an estimated $4.74M.
- 145 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2020, down from 148 in Q4 2019.
- Funds reported $242M of Alaunos Therapeutics stock for Q1 2020, down 40% quarter-over-quarter.
- 23 funds opened new Alaunos Therapeutics positions in Q1 2020 and 23 closed out, a net change of 0 holders.
- The largest Alaunos Therapeutics buyer in Q1 2020 was Discovery Capital Management, an estimated $16.7M added.
- The largest Alaunos Therapeutics seller in Q1 2020 was Millennium Management, an estimated $4.74M sold.
Based on aggregated 13F filings for Q1 2020.